AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)‘s stock had its “buy” rating restated by stock analysts at Seaport Global Securities in a note issued to investors on Friday, Marketbeat reports.

Several other analysts have also commented on the stock. Piper Jaffray Companies set a $2.00 price objective on shares of AVEO Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, June 24th. FBR & Co restated a “buy” rating and issued a $3.00 price objective on shares of AVEO Pharmaceuticals in a report on Friday, June 30th. ValuEngine upgraded shares of AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, June 24th. BidaskClub upgraded shares of AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 16th. Finally, Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a report on Monday, July 24th. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $3.42.

AVEO Pharmaceuticals (NASDAQ:AVEO) opened at 3.81 on Friday. The stock has a 50 day moving average price of $3.63 and a 200 day moving average price of $1.97. The company’s market capitalization is $450.75 million. AVEO Pharmaceuticals has a 52-week low of $0.50 and a 52-week high of $4.24.

TRADEMARK VIOLATION NOTICE: “Seaport Global Securities Reiterates “Buy” Rating for AVEO Pharmaceuticals, Inc. (AVEO)” was published by Daily Political and is owned by of Daily Political. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.dailypolitical.com/2017/10/10/aveo-pharmaceuticals-inc-aveo-research-coverage-started-at-seaport-global-securities.html.

A number of institutional investors and hedge funds have recently modified their holdings of AVEO. Fore Research & Management LP purchased a new stake in AVEO Pharmaceuticals in the second quarter worth about $111,000. Paloma Partners Management Co purchased a new stake in AVEO Pharmaceuticals in the first quarter worth about $184,000. Cannell Peter B & Co. Inc. lifted its holdings in AVEO Pharmaceuticals by 22.9% in the second quarter. Cannell Peter B & Co. Inc. now owns 109,875 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 20,500 shares during the period. Clear Harbor Asset Management LLC purchased a new stake in AVEO Pharmaceuticals in the second quarter worth about $289,000. Finally, UBS Oconnor LLC purchased a new stake in AVEO Pharmaceuticals in the first quarter worth about $291,000. Institutional investors and hedge funds own 53.76% of the company’s stock.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.